Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
Kristian Reich, Christopher EM Griffiths, Kenneth B Gordon, Kim A Papp, Michael Song, Bruce Randazzo, Shu Li, Yaung-Kaung Shen, Chenglong Han, Alexa B Kimball, April W Armstrong, Peter Foley, Andrew Blauvelt
Journal of the American Academy of Dermatology | MOSBY-ELSEVIER | Published : 2020
BACKGROUND: Long-term maintenance treatment is required for patients with psoriasis. OBJECTIVES: To evaluate the efficacy and safety of guselkumab in patients with moderate to severe psoriasis through 3 years of treatment. METHODS: In 2 ongoing, phase 3 trials of guselkumab (VOYAGE 1 and VOYAGE 2), the proportions of patients achieving at least 90% and 100% improvement in the Psoriasis Area and Severity Index (PASI 90 and PASI 100, respectively) and Investigator's Global Assessment (IGA) scores of 0/1 and 0 were summarized for the guselkumab group (including placebo-to-guselkumab crossover). Patients who met treatment failure rules were considered nonresponders. Safety outcomes (rates/100 pa..View full abstract
VOYAGE 1 and VOYAGE 2 were funded by Janssen Research & Development, LLC, Spring House, PA.